Lv61
2360 积分 2024-10-11 加入
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Nephrotoxicity: A Position Statement from the American Society of Onco-nephrology
2小时前
已完结
The Accelerated Approval Program for Cancer Drugs — Finding the Right Balance
11天前
已完结
Overall survival assessment in cancer drug trials: a luxury or a necessity?
11天前
已完结
Emerging Role of Pathologic Response in Head and Neck Squamous Cell Carcinoma Immunotherapy
20天前
已完结
Immunohistochemical Assessment of Lymphovascular Invasion in Stage I Colorectal Carcinoma
1个月前
已关闭
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer
1个月前
已关闭
Hepatocellular carcinoma
1个月前
已完结
Evolution of the Randomized Clinical Trial in the Era of Precision Oncology
2个月前
已完结
Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021
2个月前
已完结
Common Sense Oncology: outcomes that matter
2个月前
已完结
皖公网安备34019202002308
